Precigen Total Non-Operating Income/Expense 2012-2024 | PGEN

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Precigen total non-operating income/expense from 2012 to 2024. Total non-operating income/expense can be defined as the sum of all non-operating expenses for the given industry.

Precigen Total Non-Operating Income/Expense 2012-2024 | PGEN

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Precigen total non-operating income/expense from 2012 to 2024. Total non-operating income/expense can be defined as the sum of all non-operating expenses for the given industry.

Related Stocks
Company Name	Market Cap
Amgen (AMGN)	$174.8B
Vertex Pharmaceuticals (VRTX)	$133.1B
Gilead Sciences (GILD)	$120.2B
Bristol Myers Squibb (BMY)	$109.8B
Regeneron Pharmaceuticals (REGN)	$91B
CSL (CSLLY)	$90.5B
GSK (GSK)	$75.2B
Alnylam Pharmaceuticals (ALNY)	$35.8B
Argenex SE (ARGX)	$35.6B
BioNTech SE (BNTX)	$26.3B
Biogen (BIIB)	$25.2B
Illumina (ILMN)	$24B
BeiGene (BGNE)	$20B
Moderna (MRNA)	$18B
Incyte (INCY)	$16.1B
Genmab (GMAB)	$15.3B
Vaxcyte (PCVX)	$13.3B
Insmed (INSM)	$13.2B
BioMarin Pharmaceutical (BMRN)	$12.8B
Bio-Techne Corp (TECH)	$12.1B
Sarepta Therapeutics (SRPT)	$11.6B
Exelixis (EXEL)	$10.4B
Revolution Medicines (RVMD)	$10.2B
QIAGEN (QGEN)	$10B
Intra-Cellular Therapies (ITCI)	$9.7B
Exact Sciences (EXAS)	$9.5B
Bio-Rad Laboratories (BIO.B)	$9.4B
Roivant Sciences (ROIV)	$8.8B
Repligen (RGEN)	$7.9B
Halozyme Therapeutics (HALO)	$7.8B